Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.

Slides:

Advertisements

Similar presentations

San Antonio Breast Cancer Symposia Authors: Dr. Sunil Verma Date posted: January 6 th, 2008.

Advertisements

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.

Xeloda X-panding options in the adjuvant treatment of breast cancer

Oncologic Drugs Advisory Committee

Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.

The Call (a brief tour of breast cancer) Family Medicine Review Course 2011 Christian Cable, MD, FACP.

Ibrance® - Palbociclib

Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.

Cell Signaling Lecture 10. Receptor Tyrosine Kinases Regulate cell proliferation, differentiation, cell survival and cellular metabolism The signaling.

Targeted Therapy: A Giant Step Forward

Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.

update in metastatic breast cancer

6 months versus 12 months of adjuvant trastuzumab for patients with HER2- positive early breast cancer (PHARE): a randomised phase 3 trial Speaker: 陳鴻明.

A Phase III, Randomized, Double-Blind, Placebo-Controlled Registration Trial to Evaluate the Efficacy and Safety of Placebo + Trastuzumab + Docetaxel vs.

HERA: KEY DESIGN ELEMENTS, RESULTS AND FUTURE PLANS NSABP 17 SEPTEMBER 2005 Brian Leyland-Jones Minda De Gunzberg Professor of Oncology, McGill University,

A randomized three-arm multi-centre comparison of: 1 year Herceptin®1 year Herceptin® 2 years Herceptin®2 years Herceptin® or no Herceptin®or no Herceptin®

NCCTG N9831 May 2005 Update Perez EA, Suman VJ, Davidson N, Martino S, Kaufman P, on Behalf of NCCTG, ECOG, SWOG, CALGB.

Should clinicians routinely recommend trastuzumab (Herceptin) as part of the adjuvant therapy for all patients with Her2 positive early breast cancer?

Trials of Adjuvant Trastuzumab in HER2+ Early-Stage Breast Cancer Trial Study Regimen No. of Patients Disease-Free Survival (%) Hazard Ratio P-Value Overall.

Assistant Professor of Medicine Dana-Farber Cancer Institute

Abstract Introduction  What is a Herceptin (Trastuzumab) ?  Herceptin (Trastuzumab) is an monoclonal antibody,it is an example of targeted therapy an.

HER2 POSITIVE BREAST CARCINOMA IN THE PRE AND POST ADJUVANT ANTI-HER-2 THERAPY ERA: A SINGLE ACADEMIC INSTITUTION EXPERIENCE IN THE SETTING OUTSIDE OF.

Herceptin ® adjuvant therapy: “a triumphal narrative of translational research” Brian Leyland-Jones McGill University Department of Oncology Montreal,

Sunil Verma MD, MSEd, FRCPC Medical Oncologist

1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.

BASED ON PROTOCOL VERSION 1 SEPTEMBER 2012 A new study evaluating an investigational drug to treat patients with HER2-positive metastatic gastroesophageal.

Snyder D, Heidel RE, Panella T, Bell J, Orucevic A University of Tennessee Medical Center – Knoxville Departments of Pathology, Surgery, and Medicine BREAST.

Trastuzumab plus Adjuvant Chemotherapy for HER2-Positive Breast Cancer: Final Planned Joint Analysis of Overall Survival from NSABP B-31 and NCCTG N9831.

E2100 A Randomized Phase III Trial of Paclitaxel versus Paclitaxel plus Bevacizumab as First- Line Therapy for Locally Recurrent or Metastatic Breast Cancer.

Extended adjuvant treatment with anastrozole: results from the ABCSG Trial 6a R Jakesz, H Samonigg, R Greil, M Gnant, M Schmid, W Kwasny, E Kubista, B.

AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.

Cortés J et al. ASCO 2009; Abstract (Poster Discussion)

Baselga J et al. Proc SABCS 2010;Abstract S3-3.

HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.

Responses to Subsequent Anti-HER2 Therapy After Treatment with Trastuzumab-DM1 in Women with HER2- Positive Metastatic Breast Cancer 1 A Phase Ib/II Trial.

Carboplatin Not Inferior to Radiation as Adjuvant Therapy for Stage I Seminoma Slideset on: Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose.

Response-Guided Neoadjuvant Chemotherapy for Breast Cancer Gunter von Minckwitz, Jens Uwe Blohmer, Serban Dan Costa, Carsten Denkert, Holger Eidtmann Journal.

PHASE II RANDOMIZED STUDY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 – POSITIVE.

Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.

CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.

PHARE Trial Results of Subset Analysis Comparing 6 to 12 Months of Trastuzumab in Adjuvant Early Breast Cancer Pivot X et al. Proc SABCS 2012;Abstract.

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis.

Addition of Chemotherapy to Preoperative Radiotherapy Improves Outcomes in Rectal Cancer Slideset on: Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal.

MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer CCO Independent.

CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer José Baselga, M.D., Ph.D., Javier Cortés, M.D., Sung-Bae Kim, M.D., Seock-Ah Im,

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 KRISTINE: Neoadjuvant T-DM1 + Pertuzumab vs Chemotherapy With Trastuzumab.

CCO Independent Conference Coverage

Slamon D et al. SABCS 2009;Abstract 62.

Neoadjuvant Palbociclib + Anastrozole in ER+/HER2- Breast Cancer

Number of brain metastasis

Comparison between Pathologic Characteristics of Her2 Negative and Positive Breast Cancer in a Single Cancer Center in Jordan DR Majdi A. Al Soudi, MD,

Update in Treatment of Early Breast Cancer

CCO Independent Conference Highlights

A Single-Arm Phase IIIb Study of Pertuzumab and Trastuzumab with a Taxane as First-Line Therapy for Patients with HER2-Positive Advanced Breast Cancer.

Perez EA et al. SABCS 2009;Abstract 80.

CREATE-X: Adjuvant Capecitabine in HER2-Negative Breast Cancer

Blackwell KL et al. SABCS 2009;Abstract 61

Vahdat L et al. Proc SABCS 2012;Abstract P

Tab. 1 – Characteristics of patients

SAFETY AND EFFICACY OF EVEROLIMUS PLUS EXEMESTANE IN METASTATIC BREAST CANCER BEYOND THE SECOND LINE TREATMENT: A SINGLE INSTITUTION EXPERIENCE M. Giampaglia,

Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results.

Her2-positive breast cancer: updating current best practice

Krop I et al. SABCS 2009;Abstract 5090.

Jones SE et al. SABCS 2009;Abstract 5082.

Untch M et al. Proc SABCS 2010;Abstract P

Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011

20-Year Risks of Breast-Cancer Recurrence

Published online Feb 7, 2019 Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling:

Presentation transcript:

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:

clinicaloptions.com/onco Oncology Journal Options Piccart-Gebhart M, et al. N Engl J Med. 2005;353: Background and Rationale  HER2 protein overexpression and/or HER2 gene amplification –Seen in 15%-20% of women with breast cancer –Linked to rapid tumor growth  Trastuzumab effective in women with metastatic HER2-positive breast cancer –This monoclonal antibody targets the extracellular domain of the HER2 protein –Acts as HER2 receptor antagonist

clinicaloptions.com/onco Oncology Journal Options Piccart-Gebhart M, et al. N Engl J Med. 2005;353: Baseline Characteristics Characteristic 1 Yr Trastuzumab, n (%) (n = 1694) Observation, n (%) (n = 1693) Nodes Negative 1-3 positive  4 positive 543 (32.1) 482 (28.5) 480 (28.3) 557 (32.9) 490 (28.9) 473 (27.9) Hormone receptor ER negative/PR negative ER negative/PR positive ER positive/PR positive ER positive/PR negative 798 (47.1) 88 (5.2) 526 (31.1) 210 (12.4) 817 (48.3) 85 (5.0) 459 (27.1) 246 (14.5) Tumor grade 3 (poorly differentiated) 2 (moderately differentiated) 1 (well differentiated) 1015 (59.9) 546 (32.2) 45 (2.7) 1012 (59.8) 554 (32.7) 42 (2.5) Chemotherapy No anthracyclines Anthracyclines, no taxanes Anthracyclines + taxanes 102 (6.0) 1151 (67.9) 440 (26.0) 104 (6.1) 1156 (68.3) 433 (25.6) ER, estrogen receptor; PR, progesterone receptor.

clinicaloptions.com/onco Oncology Journal Options Piccart-Gebhart M, et al. N Engl J Med. 2005;353: Summary of Study Design Patients with HER2-positive breast cancer treated with surgery, chemotherapy ± radiation Trastuzumab Initial dose, 8 mg/kg IV, then 6 mg/kg every 3 weeks for 1 year (n = 1694) Observation (n = 1693) Interim analysis † 1:1 randomization* *Randomization  7 weeks from first day of last chemotherapy cycle or  6 weeks from end of surgery or radiation, whichever was later. † Performed after 475 events were reported. Third arm of trastuzumab for 2 years (n = 1694) not reported as part of this interim analysis.

clinicaloptions.com/onco Oncology Journal Options Piccart-Gebhart M, et al. N Engl J Med. 2005;353: Main Findings Study Endpoint 1 Yr Trastuzumab* (n = 1694) Observation* (n = 1693) Hazard RatioP Value 2-year disease-free survival85.8 (83-89)77.4 (74-81)0.54 ( )< year freedom from distant recurrence 90.6 (88-93)82.8 (80-86)0.49 ( )< year overall survival96.0 (94-98)95.1 (93-97)0.76 ( ).26 *% patients (95% confidence interval).

clinicaloptions.com/onco Oncology Journal Options Piccart-Gebhart M, et al. N Engl J Med. 2005;353: Key Conclusions  Adjuvant trastuzumab effective for HER2-positive breast cancer patients after primary therapy –Disease recurrence decreased, especially distant recurrence –No significant difference in overall survival  Low rate of cardiac toxicity, but significantly greater than in control group  1-year course of adjuvant trastuzumab recommended as standard treatment